Serum Adiponectin in Chinese Population and Its Correlation to Cardiovascular and Cerebrovascular Diseases

Air Force Military Medical University of People's Liberation Army

Status: Enrolling

Conditions: Cerebral Infarction; Myocardial Infarction

Study type: Observational

Funder types: Other

Identifiers

NCT01372800

xj050503

Details and patient eligibility

About

Adiponectin (Ad) is an abundant protein in human body, and reports have shown that it act as a novel risk factor for brain and heart ischemia injury. This 5 years follow-up study will focus on serum adiponectin concentration, activity and isoforms in Chinese population and its correlation to these diseases.

Full description

Adiponectin (Ad) is an abundant protein hormone regulatory of numerous metabolic processes, anti-inflammatory, vascular protective, and anti-ischemic properties. Since its 1995 discovery, Ad has garnered considerable attention for its role in diabetic and cardiovascular pathology. Clinical observations have demonstrated the association of hypoadiponectinemia in patients with obesity, cardiovascular disease, and insulin resistance. There is growing evidence supporting Ad can act as a novel risk factor for cardiovascular and cerebrovascular injury. This 5 years follow-up study will focus on serum adiponectin concentration, activity and isoforms in Chinese population and its correlation to cardiovascular and cerebrovascular diseases.

Enrollment: 30,000 estimated patients

Sex: All

Ages: 18 to 85 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• available for 5 years of follow-up study

Exclusion criteria

• Death caused other than cardiovascular and cerebralvascular diseases till the study ends
• Floating Population
• Pregnancy, lactation, or child bearing women
• Tumor
• Active hepatic disease or hepatic dysfunction, or AST/ALT > 1.5UNL
• Severe renal dysfunction(Scr > 3 mg/dl or 264μmol/L)
• Patients with any condition which, in the investigator's judgment, might increase the risk to the subject for any adverse event or abnormal laboratory finding

Trial design

30,000 participants in 1 patient group

volunteer